Adam J. Townsend, Chief Commercial Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 10,000 shares at $82.71 ($827K) on 2023-05-03, disclosed to the SEC on 2023-05-04.
Scheduled sale ($827k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.71 | 5,000 | $414K | 50.0% |
| 2 | $82.71 | 5,000 | $414K | 50.0% |
| Total | $82.71 avg | 10,000 | $827K | 100% |
| Filing → |
| APLS | SELL | 2025-01-21 | $132K | — | Filing → |
| APLS | SELL | 2025-01-14 | $154K | — | Filing → |
| APLS | SELL | 2024-02-13 | $156K | — | Filing → |